URGN Q2 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+27.4% YoY

Gross Profit

$15M88.9% margin

Operating Income

-$19M-112.7% margin

Net Income

-$27M-160.8% margin

EPS (Diluted)

$-1.18

QoQ Revenue Growth

+22.4%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$146M

Total Liabilities

$187M

Stockholders' Equity

-$41M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$13M	+27.4%
Gross Profit	$15M	$12M	+27.2%
Operating Income	-$19M	-$23M	+18.0%
Net Income	-$27M	-$26M	-1.8%

Revenue Segments

Jelmyto

$17M100%